All In Biotech

NDA 021073 · Takeda Pharms USA

Actos

Pioglitazone Hydrochloride · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Dec 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Jul 15, 1999

Approved uses

6

Original approval plus efficacy supplements

Registered trials

524

126 Phase 3, 31 recruiting

FAERS reports

43,198

30,844 serious, 4,332 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CONGESTIVE HEART FAILURE • Thiazolidinediones, including ACTOS ® , cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . • After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered. • ACTOS is not recommended in patients with symptomatic heart failure. • Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: CONGESTIVE HEART FAILURE See full prescribing information for complete boxed warning. •...

What it is approved for

From the label in effect Mar 28, 2025.

Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . Important Limitations of Use ACTOS exerts its antihyperglycemic effect only in the presence of endogenous insulin. ACTOS should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions (5.3) ] . ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ( 1 , 14 ) Important Limitations of Use: • Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1)

Mechanism: ACTOS is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. ACTOS decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ACTOS · PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE · TABLET, ORAL · Prescription · TE AB
  • ACTOS · PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB
  • ACTOS · PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pioglitazone" as an intervention, any sponsor and status, largest first.

All 524 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bladder cancer8,740
  • blood glucose increased3,398
  • nausea3,007
  • weight decreased2,092
  • diarrhoea1,757
  • death1,553
  • fatigue1,532
  • drug ineffective1,513
  • vomiting1,495
  • dyspnoea1,426
  • dizziness1,422
  • decreased appetite1,420

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004870
20051,323
20062,362
20072,679
20081,644
20091,880
20102,186
20113,106
20122,039
20131,282
20141,127
20156,601
20163,836
20171,859
20181,860
20191,684
20201,378
20211,090
2022984
2023906
2024952
2025913
2026637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Actos (Pioglitazone HCl)

2024 spending

$650K

Beneficiaries

168

625 claims

Per beneficiary

$3,872

$16.54 per unit

View as table
YearSpending
2020$2,092,476
2021$1,749,928
2022$1,353,112
2023$947,844
2024$650,459

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,174 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.